Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

Autism Clinical Trial

Official title:
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine

Status Completed

Clinical Trial Summary

The purpose of this randomized withdrawal study is to evaluate the safety, tolerability, and efficacy of memantine compared with placebo in pediatric patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).

Clinical Trial Description

This clinical study was a 12-week, multicenter, double-blind, placebo-controlled, randomized withdrawal study in pediatric outpatients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). Patients who completed at least 12 weeks of study drug exposure and met protocol specified responder criterion in lead in Study MEM-MD-91 (NCT01592786) at two consecutive visits separated by at least two weeks were eligible to transition to this study. The responder criterion was defined as having at least a 10 point improvement (reduction in score) in the Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 total raw score in Study MEM-MD-91.

Weight based dose limits were selected in this study to ensure that exposure in terms of area under the curve (AUC) was less than the predefined limit of 2100 ng·h/mL which represents a 10-fold lower exposure than observed at the NOAEL(No observed adverse effect level) of 15 mg/kg/day in juvenile rats.

The weight-based dose limits in this study were as follows:

- Group A: ≥ 60 kg; maximum 15 mg/day

- Group B: 40-59 kg; maximum 9 mg/day

- Group C: 20-39 kg; maximum 6 mg/day

- Group D: < 20 kg; maximum 3 mg/day ;

Study Design

Related Conditions & MeSH terms

Asperger Syndrome
Asperger's Disorder
Autism
Autism Spectrum Disorder
Autism Spectrum Disorders
Autistic Disorder
Child Development Disorders, Pervasive
Developmental Disabilities
Disease
Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)

Clinical Trial Details

NCT number	NCT01592747
Study type	Interventional
Source	Forest Laboratories
Contact
Status	Completed
Phase	Phase 2
Start date	September 2012
Completion date	October 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05302167` - Molehill Mountain Feasibility Study.	N/A
Completed	`NCT04167839` - Effects of Sensory Diets on Children's Sensory Processing Skills, Psychosocial Skills, and Classroom Engagement	N/A
Terminated	`NCT04049981` - Investigation of Mechanisms of Action in Superpower Glass	Phase 1/Phase 2
Active, not recruiting	`NCT06080087` - Implementation Toolkit to Enhance EBP Among Marginalized Families	N/A
Recruiting	`NCT04107064` - Achieving Steady Work Among Adults With Autism Through Specialized Employment Program	N/A
Completed	`NCT03206996` - Exposure Therapy for Auditory Sensitivity in Autism	N/A
Completed	`NCT01914393` - Pediatric Open-Label Extension Study	Phase 3
Completed	`NCT05588570` - Coaching Children With Anxiety and Autism Through Telehealth	N/A
Enrolling by invitation	`NCT06058104` - Evaluating Efficacy of a Digital Game Therapeutic for Children With Autism	N/A
Withdrawn	`NCT02414451` - Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response	N/A
Completed	`NCT02847182` - Cord Blood Infusion for Children With Autism Spectrum Disorder	Phase 2
Completed	`NCT02911194` - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)	N/A
Completed	`NCT03002363` - The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance	Phase 1
Completed	`NCT02720900` - Prebiotic Intervention for Autism Spectrum Disorders	N/A
Completed	`NCT02536365` - Sensory Integration Therapy in Autism: Mechanisms and Effectiveness	N/A
Completed	`NCT02708290` - Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
Completed	`NCT02508922` - Trial of Vitamin D3 Supplementation in Paediatric Autism	N/A
Recruiting	`NCT01836562` - A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism	Phase 1/Phase 2
Recruiting	`NCT02255565` - Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study	Phase 4
Completed	`NCT02154828` - Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.